Drugmakers are placing big bets on medicines they expect will command premium prices. Sanofi made an unsolicited, $9.3 billion offer to purchase Medivation. Separately, AbbVie agreed to pay $5.8 billion for Stemcentrx.
from WSJ.com: US Business http://ift.tt/1SwHCei
via IFTTT
No comments:
Post a Comment